Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
1996-2-28
|
pubmed:abstractText |
To evaluate the efficacy and safety of low dose (10 mg) pravastatin in hypercholesterolemic, hypertensive elderly subjects undergoing antihypertensive treatment, a randomized, double-blind, placebo-controlled 6-month trial was conducted. The subjects had a total plasma cholesterol of at least 250 mg/dL and had been, for at least 3 months, consuming a standard lipid-lowering diet (American Heart Association Step 1 Diet). Sixty elderly hypertensive patients randomly received placebo (n = 30) or pravastatin (n = 30) treatment. The dosage consisted of 10 mg of pravastatin daily during the 6-month trial. Over that period, in the pravastatin group, plasma levels of total cholesterol and LDL-cholesterol significantly (P < .01) dropped (-20% and -25%, respectively) compared to the placebo group. The plasma level of HDL-cholesterol increased (+5%) while triglycerides slightly decreased (-8%) (P < .05). No serious side effects occurred, and pravastatin was generally tolerated. Fasting hyperinsulinemia (11.0 +/- 0.8 v 9.3 +/- 0.7 microU/mL; P = .06) also improved, although not significantly, after 6 months of pravastatin therapy. Results from this study confirmed that a low dose (10 mg) of pravastatin daily is a safe and effective method of reducing plasma total and LDL-cholesterol in hypercholesterolemic, hypertensive elderly patients who are on concurrent antihypertensive drug therapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anticholesteremic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, HDL,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Placebos,
http://linkedlifedata.com/resource/pubmed/chemical/Pravastatin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0895-7061
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1099-104
|
pubmed:dateRevised |
2009-2-24
|
pubmed:meshHeading |
pubmed-meshheading:8554733-Aged,
pubmed-meshheading:8554733-Anticholesteremic Agents,
pubmed-meshheading:8554733-Antihypertensive Agents,
pubmed-meshheading:8554733-Cholesterol, HDL,
pubmed-meshheading:8554733-Cholesterol, LDL,
pubmed-meshheading:8554733-Double-Blind Method,
pubmed-meshheading:8554733-Female,
pubmed-meshheading:8554733-Humans,
pubmed-meshheading:8554733-Hypercholesterolemia,
pubmed-meshheading:8554733-Hypertension,
pubmed-meshheading:8554733-Male,
pubmed-meshheading:8554733-Patient Compliance,
pubmed-meshheading:8554733-Placebos,
pubmed-meshheading:8554733-Pravastatin
|
pubmed:year |
1995
|
pubmed:articleTitle |
The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy.
|
pubmed:affiliation |
Department of Cardiology, Taipei Municipal Chung-Hsiao Hospital, Taiwan.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|